Renovo announced that its mid-stage trial of Prevascar to reduce skin scarring hit its primary endpoint and multiple secondary endpoints. "As well as refining Prevascar's optimal dose in the skin, we intend to diversify our scar prevention product portfolio further by investigating the efficacy of Prevascar in the prevention of scarring following peripheral nerve injury," said Renovo CEO Mark Ferguson. Ferguson also said that talks to partner with another company on Juvista, its lead therapy, are progressing.
- check out this release on the data
- read the report on Renovo from Hemscott
ALSO: Renovo's successful IPO has been held up as an example of how the European biotech industry has recovered. Report